Insulin-like growth factor 1 is often discussed as though its name alone predicts an outcome. Reading the research requires more detail: which molecule was present, what else bound it, and whether the experiment changed a protein, a receptor or an entire developing organism. This reference connects those questions through original structural and genetic studies.
Identify the molecule behind a structure image
The human IGF-1 chain deposited in structure 1IMX contains 70 residues. The record distinguishes this deposited sequence from the smaller set of residues modelled in its crystal coordinates.Vajdos and colleagues — Human IGF-1 crystal structure, PDB 1IMX (opens in a new tab)
That distinction matters when reading a molecular illustration. A region missing from the displayed coordinates has not necessarily been removed from the experimental molecule. Read the sequence and construct fields before interpreting the picture as a complete chemical definition.
Vajdos and colleagues found crystal contacts resembling an IGF-1 dimer, while analytical ultracentrifugation supported a monomer at physiological concentrations. Their crystallisation detergent also interfered with interactions involving certain IGF binding proteins.Vajdos and colleagues — Human IGF-1 crystal structure, PDB 1IMX (opens in a new tab)
A crystal therefore records an experimentally informative arrangement under particular conditions. It should not be treated as a photograph of every form the molecule takes in circulation. For comparisons, retain both the chain identity and the environment used to observe it.
Include the binding partners in the evidence record
Sitar and colleagues examined IGF-1 complexes containing amino- and carboxyl-terminal fragments of IGF binding proteins. The structures showed contacts that partly covered regions needed for receptor binding.Sitar and colleagues — IGF binding-protein complexes, PDB 2DSP (opens in a new tab)
Their three-component structural complex consisted of IGF-1 plus separate binding-protein domains. This is a specific experimental meaning of ternary complex; the phrase alone does not identify a circulating complex or its members.Sitar and colleagues — IGF binding-protein complexes, PDB 2DSP (opens in a new tab)
| Detail | Why it changes interpretation |
|---|---|
| Free or bound ligand | The binding interface may be accessible in one state and covered in another |
| Full protein or domain | An isolated fragment does not reproduce every property of the full partner |
| Named complex members | The number of components does not identify their chemistry |
When two papers report different interaction strengths, compare the partners before treating the numbers as contradictory. A measurement involving an isolated domain and one involving a complete protein need not describe the same molecular event.
What gene deletion can and cannot answer
Liu and colleagues’ 1993 mouse study disrupted Igf1 and its receptor gene. Loss of the ligand and loss of the receptor produced different growth and survival phenotypes; the survival of Igf1-null animals also depended on genetic background.Liu and colleagues — Mice carrying null mutations of Igf-1 and Igf1r (opens in a new tab)
This supports an important developmental role for the pathway. It does not make deletion of the ligand interchangeable with deletion of the receptor, or turn either manipulation into a model of ordinary adult variation.
The direction of the experiment is essential. Removing a component during development asks what the organism requires under those conditions. Adding material later asks a different question about exposure, response and adverse effects.
Build a useful IGF-1 research note
Start the note with a concrete object: a defined human chain, a complex containing named partners, or a mouse with a particular gene disruption. This prevents one broad growth-factor heading from erasing important experimental differences.
Next state the observation in the same language as the method: a resolved contact, altered binding or a developmental phenotype. Reserve claims about tissue function, symptoms or performance for studies that measured those outcomes.
Finally, identify the remaining bridge. For a structure, it may be whether the interaction occurs in the intended biological setting. For a developmental model, it may be whether the proposed adult intervention has been tested at all.
This approach makes IGF-1 a useful biological reference without presenting every associated result as evidence for a purchasable product. Related molecules, modified analogues and formulations require their own identity and evidence records.
Sources and further detail
- Vajdos and colleagues — Human IGF-1 crystal structure, PDB 1IMX (opens in a new tab)
Original structure record and paper abstract read. Deposited versus modelled residues, detergent interference and solution versus crystal observations distinguished.
- Sitar and colleagues — IGF binding-protein complexes, PDB 2DSP (opens in a new tab)
Original structural paper abstract and deposited components checked. Ternary refers here to ligand plus two domains, not an assumed circulating complex.
- Liu and colleagues — Mice carrying null mutations of Igf-1 and Igf1r (opens in a new tab)
Original indexed 1993 abstract read. Ligand/receptor differences and background-dependent survival retained; no adult supplementation inference.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.